The statement from the REACH investigators that angiotensin-converting-enzyme (ACE) inhibitors are not associated with improved outcome in stable coronary artery disease should be interpreted with caution to avoid generating confusion or depriving patients of preventative therapy. Such observational data do not enable definitive conclusions to be drawn on treatment efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sorbets, E. et al. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu078.
Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145–153 (2000).
Fox, K. M. for the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782–788 (2003).
Braunwald, E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058–2068 (2004).
Fihn, S. D. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126, e354–e471 (2012).
Montalescot, G. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949–3003 (2013).
Cangiano, E. et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am. J. Cardiovasc. Drugs 11, 189–198 (2011).
Ceconi, C. et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc. Drugs Ther. 21, 423–429 (2007).
Ceconi, C. et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 577, 1–6 (2007).
Bangalore, S. et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308, 1340–1349 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received research grants from Boehringer Ingelheim, Irbtech, Novartis, and Servier; speakers' bureau fees from Boehringer Ingelheim and Servier; and consultancy fees (advisory board) from Bayer, Boehringer Ingelheim, Novartis, and Servier.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Ferrari, R. Use of ACE inhibitors in stable CAD—what is the truth?. Nat Rev Cardiol 11, 315–316 (2014). https://doi.org/10.1038/nrcardio.2014.56
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.56
This article is cited by
-
ARNIs: balancing “the good and the bad” of neuroendocrine response to HF
Clinical Research in Cardiology (2020)
